Published in final edited form as:

Dig Dis Sci. 2012 October ; 57(10): . doi:10.1007/s10620-012-2203-7.

Vitamin C, Gastritis, and Gastric Disease: a historical review and update

Anupam Aditi, M.D.¹ and David Y. Graham, M.D.²

¹Departments of Medicine, Washington University School of Medicine in St. Louis

²Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas

Abstract

The discovery of *Helicobacter pylori* as the cause of gastritis and peptic ulcers ushered in the modern era of research into gastritis and into acid-peptic diseases and rekindled interest in the role of ascorbic acid in the pathophysiology and treatment of gastritis and peptic ulcer disease. Here, we review historic and modern studies on ascorbic acid and gastric diseases with an emphasis on *H. pylori* gastritis and its sequelae. The relationship of ascorbic acid and gastritis and peptic ulcer and its complications was extensively studied during the 1930's through the 1950's. Much of this extensive literature has been effectively "lost". Ascorbic acid deficiency was associated with all forms of gastritis (e.g., autoimmune, chemical, and infectious) due in varying degrees to insufficient intake, increased metabolic requirements, and destruction within the GI tract. Importantly, gastritis-associated abnormalities in gastric ascorbic acid metabolism are reversed by *H. pylori* eradication and potentially worsened by proton pump inhibitor (PPI) therapy. Diets rich in naturally occurring ascorbic acid are associated with protection of the gastric corpus from atrophy and a reduction in the incidence of gastric cancer possibly through the ability of ascorbic acid to reduce oxidative damage to the gastric mucosa by scavenging carcinogenic N-nitroso compounds and free radicals and attenuating the *H. pylori*-induced inflammatory cascade. Ascorbic acid supplementation was possibly associated with a decreased incidence of bleeding from peptic ulcer disease. Pharmacologic doses of ascorbic acid also may improve the effectiveness of *H. pylori* eradication therapy. Occasionally, looking back can help plot the way forward.

Keywords

Helicobacter pylori; ascorbic acid; vitamin C; peptic ulcer; gastritis; pernicious anemia; gastric cancer; dehydroascorbic acid; intestinal metaplasia; gastrointestinal bleeding; absorption

Introduction

Vitamin C is a micronutrient essential for human health. Vitamin C deficiency results in scurvy which for centuries was a major health problem for armies and for blue water sailors. It was long known that ingestion of various plants (e.g., citrus fruits and scurvy grass) would result in clinical improvement of the disease. In addition, early human experimentation showed that scurvy could be prevented by ingestion of citrus fruits and juice, but despite this evidence the cause remained unknown and the data controversial [1]. In the late 19th and early 20th centuries, animal and human experimentation explored the etiology of pellagra,

Beri Beri, and scurvy all of which subsequently proved to be vitamin deficiency diseases [1–3]. During that period, investigators were greatly influenced by the work of Pasteur and the germ theory and although the experimental results often pointed to a relation between a food and a disease, the possibility that these diseases were microbial in origin (e.g., a result of infected corn or rice) often appeared to the investigators to be a more likely explanation than a simple deficiency of a specific nutrient [1–3].

The discovery and synthesis of what we now know as vitamins and proof that specific diseases could be rapidly reversed or prevented by administration of the specific dietary ingredients brought that phase of discovery to an end and prompted the still ongoing investigations into the role of vitamins in health and disease. Here, we explore the associations of vitamin C (ascorbic acid) in gastritis with an emphasis on *Helicobacter pylori*-associated gastritis and the *H. pylori*-associated diseases, peptic ulcer disease and gastric cancer.

Vitamin C in health and disease

Humans are unable to synthesize ascorbic acid *de novo* and must rely on dietary sources for vitamin C and its oxidation product, dehydroascorbic acid [4]. Ascorbic acid is an anti-oxidant that also plays a critical role in the production of key proteins such as collagen, norepinephrine and serotonin [4]. The daily recommendation of ascorbic acid is 90 mg for men and 75 mg for women. A wide variety of foods, such as oranges, lemons, cabbage, broccoli, tomatoes and potatoes are high in ascorbic acid and many prepared foods are now fortified with synthetic vitamin C.

Ascorbic acid and dehydroascorbic acid have equal bioavailability. Both are absorbed from the stomach and along the entire length of the small intestine via specific uptake mechanisms involving a number of trans-membrane proteins that facilitate the transport of ascorbic acid at the intestinal brush border. Ascorbic acid is absorbed across cellular membranes via two saturable transporters: the Sodium dependent Vitamin C Transporters 1 (SVCT1) and Sodium dependent Vitamin C Transporter 2 (SVCT2) [5]. Both transporters exhibit significantly higher affinities for L-ascorbic acid compared to D-ascorbic acid or dehydroascorbic acid and depend on the co-transport of two Na⁺ ions; however, the transporters differ in their protein kinetics and tissue distribution. SVCT1 has consistently been found to have a higher capacity to transport ascorbate (i.e., higher V_m), whereas SVCT2 has a slightly higher affinity for ascorbate, with a $K_{0.5}$ of 10–70 μ M versus 20–100 μ M for SVCT1. Consistent with its enzyme kinetics, SVCT1 is found largely in the bulk transporting epithelium of the small intestine, renal proximal tubule, and the liver while SVCT2 is more widely expressed. SVCT2 is located in the gastric mucosa from the base of the stomach to the isthmus and is suspected to mediate basolateral uptake of L-ascorbic acid by gastric glands against a concentration gradient [6]. Studies of ascorbate absorption have shown that both SVCT1 and SVCT2 mRNA are expressed in human intestinal epithelium. Ascorbate transport measurement and imaging analysis using the human intestinal epithelial cell line, Caco-2, revealed that SVCT1 has a predilection for localization in apical membranes [7]. Further study revealed that a region in the carboxyl-terminal portion of SVCT1 targets the protein to the apical membrane of polarized intestinal epithelial cells [7]. As in the stomach, SVCT2 is localized to the basolateral membrane of intestinal cells.

Dehydroascorbic acid absorption occurs along the entire small intestine via facilitated diffusion through sodium-independent carriers; dehydroascorbic acid competes with glucose for uptake through the mammalian glucose transporters GLUT1, GLUT3, and GLUT4 [8]. Human enterocytes contain reductases that convert dehydroascorbic acid to ascorbate, which

maintains a low intracellular concentration of dehydroascorbic acid and forms a gradient for continued dehydroascorbic acid uptake [4].

In plasma, ascorbic acid exists mainly in the form of ascorbate ion and reaches a concentration of 30–60 μM , with a maximal concentration of 90 μM , the renal threshold for complete ascorbate reabsorption [4]. Gastric gland ascorbate concentrations are three to ten times higher than plasma levels suggesting active transport of ascorbic acid into gastric tissue and kinetic analysis of ascorbic acid accumulation in KATO III and AGS gastric epithelial cells revealed the presence of a high affinity saturable transport system with a K_m of 3–11 $\mu\text{mol/L}$ [6].

Normal ascorbic acid levels

Using modern methods, the normal concentration of ascorbic acid in the serum ranges between 30 to 90 $\mu\text{mol/L}$ (0.5 and 1.6 mg/dL). Plasma values between 11 and 23 $\mu\text{mol/L}$ indicate marginal deficiency and values below 11 $\mu\text{mol/L}$ (~0.18 mg/dL) indicate deficiency [9]. These modern values are strikingly similar to those published by Theodore H. Ingalls in 1937 (Table 1) [10].

Measurement of ascorbic acid

The early 1900's was a time of great interest in ascorbic acid which culminated in 1928 when Albert Szent-Gyorgyi isolated hexuronic acid from the bovine adrenal cortex [11]. By 1933, research from the University of Pittsburgh confirmed that hexuronic acid, which had been renamed ascorbic acid, had anti-scorbutic properties [8;12;13]. In 1933, Szent-Gyorgyi isolated large amounts of ascorbic acid from Hungarian paprika and in 1937 was awarded the Nobel Prize in physiology and medicine.

In 1930, Tillmans took advantage of the reducing property of vitamin C to measure plasma and tissue ascorbic acid concentration by titration of study samples with the redox-dye 2,6 dichlorophenol indophenols [14]. Van Eekelen and Harris subsequently showed it was possible to estimate body stores of ascorbic acid measuring the urinary excretion of ascorbic acid by administration of sufficient vitamin C to saturate body stores during the saturation process [15]. They showed that it was possible to give repeated doses of ascorbic acid to subjects with depleted body stores without a concomitant increase in urinary excretion. However, when the deficiency was corrected, urinary ascorbic acid excretion would increase. The point where this occurred was defined as the saturation point. They found that the dose necessary to produce saturation was associated with a plasma level of 1.4 mg/dL and was inversely proportional to the level of depletion of vitamin C stores in the body [15]. This approach provided a simple, practical test to assess the degree of hypovitaminosis and was subsequently used by many investigators as a clinical test to examine the role of ascorbic acid deficiency in disease [16].

Ascorbic acid deficiency in peptic ulcer and gastritis

Using the ascorbic acid saturation test in control patients who ingested the “minimal optimal” daily dose of ascorbic acid of 25 mg/day, Harris et al. identified the daily urinary excretion of the minimal optimal stores to be 13 mg/day [16]. In 1936, Harris et al. measured vitamin C stores in 74 hospitalized patients including 19 with gastric ulceration or dyspepsia [16]. They found that the average daily excretion of ascorbic acid among hospitalized patients was lower than the minimal optimal stores (8.9 mg/day vs. 13 mg/day). Furthermore, the 19 gastric ulceration and dyspepsia patients had an average excretion of only 5.6 mg/day. That same year Archer and Graham studied the body saturation of ascorbic

acid in 9 patients with gastric or duodenal ulcer and found 6 (66.6%) to have urinary excretion less than 13 mg/day (Figure 1) [17].

In 1937, Ingalls studied the urinary excretion of ascorbic acid in children and concurrently measured plasma levels to establish the plasma values for ascorbic acid deficiency (Table 1) [18]. Later that year, Ingalls and Warren compared ascorbic acid levels in 20 peptic ulcer patients with 2 healthy hospital workers. The ulcer patients had an average plasma ascorbic acid approximately 15% of controls (0.19 mg/dL compared to 1.25 mg/dL) [10]. In 1940, Field et al. reported that 39 of 58 ulcer patients had blood ascorbic acid levels below 0.5 mg/dL, which is considered a borderline scorbutic level [19]. Twelve (31%) of these patients suffered gastrointestinal bleeding during the study and 10 of these had plasma ascorbic acid levels of less than 0.4 mg/dL [19]. In 1941, Riggs et al. reported that the average plasma ascorbic acid level among 53 ulcer patients was 0.24 mg/dl compared to 0.52 mg/dL for 15 controls [20].

In 1938, Portnoy and Wilkinson evaluated the effect of oral and intravenous administration of 1,000 mg of ascorbic acid on total body ascorbic acid stores [21]. They studied 107 subjects including 26 normal controls, 25 hospitalized patient controls, 25 ulcer patients without a GI bleed, and 31 ulcer patients with a GI bleed. The plasma ascorbic acid levels of the control groups ranged from 0.60 to 1.85 mg/dL compared to 0.14 to 0.59 mg/dL in those with peptic ulcer. Oral administration of 1,000 mg of ascorbic acid to the controls resulted in a rapid increase in plasma ascorbic acid in the first two hours with peaks between 1.80 and 3.5 mg/dL and the urinary concentration of ascorbic acid showed “a maximal increase”. In contrast, ulcer patients with initial low ascorbic acid values showed increases to plasma levels of only 0.48 to 0.60 mg/dL with little or no increases in urinary levels. Using the urinary excretion ascorbic acid saturation test (the excretion rate for patients with “minimal optimal” stores being 13 mg/day) they reported that the urinary ascorbic acid excretion was normal for non-hospitalized controls (29 mg/day) and for hospitalized controls (17 mg/day). In contrast, ulcer patients had daily ascorbic acid urinary excretion of only 7 mg/day. The amount of ascorbic acid needed to saturate body stores was between 500 and 1,000 mg for non-hospitalized controls, 1,252 mg for hospitalized controls, 3,691 mg for ulcer patients without bleeding and 4,543 mg for ulcer patients who had bled (Table 2) [21].

In 1947, Crescenzo and Cayer studied ascorbic acid loading in ulcer patients and controls [22]. They obtained fasting plasma ascorbic acid levels and subsequently provided a 1,000 mg loading dose of ascorbic acid. The plasma ascorbic acid concentration was assessed hourly for three hours after ascorbic acid loading; the results confirmed the prior observations that patients with peptic ulcer, especially those with ulcer hemorrhage, typically had ascorbic acid deficiency (Table 3) [22].

In 1957, Freeman and Hafkesbrink compared the plasma and gastric fluid ascorbic acid concentrations (which were known to reliably represent the total body stores of ascorbic acid) of 108 patients with gastric disease and 113 controls [23]. They showed that mean plasma and mean gastric ascorbic acid level were 50% and 42% respectively lower in those with gastritis, peptic ulcer disease, pernicious anemia and gastric cancer compared to controls (Figure 2) [23]. Importantly, as will be emphasized below, low ascorbic acid levels were shown to be present in pernicious anemia, a non-*H. pylori* form of gastritis.

Mechanisms of ascorbic acid deficiency in gastric diseases

Increasing evidence of a high prevalence of ascorbic acid deficiency amongst peptic ulcer patients led to investigations into the role of vitamin C in the pathogenesis and the course of peptic ulcer disease. Researchers studied whether ascorbic acid deficiency played a role in

the pathogenesis of the ulcer or its complications as well as whether ascorbic acid therapy would treat the ulcer or prevent ulcer complications. Ludden et al. proposed 4 factors that might be responsible for ascorbic acid deficiency in gastrointestinal disease including: 1) decreased absorption, 2) insufficient intake, 3) increased metabolic requirement, and 4) rapid destruction in the GI tract [24].

Decreased Absorption

Ludden et al. reported no differences in ascorbic acid absorption between controls and patients with superficial gastritis, chronic hypertrophic gastritis or peptic ulcer disease [24]. These findings are in accordance with current knowledge that ascorbic acid can be absorbed along the entire small intestine (i.e., at sites distant from the gastric inflammation present in peptic ulcer disease). The authors did however note that patients with chronic atrophic gastritis had diminished absorption and suggested this was likely due to destruction of ascorbic acid in the gastric mucosa, possibly by elevated pH and bacterial overgrowth.

Insufficient Intake

Until recently, foods were not fortified with vitamins and adequate vitamin intake relied solely on the diet. In many regions, maintaining adequate levels was particularly difficult, especially where winters were severe and ascorbic acid-containing foods often became scarce or unavailable. In addition, previously physicians relied heavily on diets for the treatment of gastrointestinal diseases and many authors during that period suggested that insufficient intake was likely a major cause or a contributor to ascorbic acid deficiency in peptic ulcer patients. The Sippy diet in particular, which consisted of milk, cream, cereal and eggs, was severely deficient in ascorbic acid [25]. For example, Ebbesen and Rasmussen assessed the plasma ascorbic acid level of 60 ulcer patients on the day of admission to the hospital [26]. All were started on the standard ulcer diet and their plasma ascorbic acid levels were reassessed at three to six day intervals. By the twelfth to sixteenth day, plasma ascorbic acid levels had dropped by an average of 75% [26]. Of interest, in 1928 Davidson presented 3 cases of severe scurvy secondary to adherence to ulcer diets [27] and in 1936 Platt presented 3 additional cases showing that lessons in medicine are often learned slowly [28].

A recent study suggested that a significant difference in vitamin C intake might exist amongst *H. pylori* positive and negative patients in that the average amount ingested in 14 *H. pylori* positive subjects was 35.9 mg daily compared to 130.9 mg among 15 *H. pylori* negative subject ($p<0.01$) [29].

Increased metabolic requirement

Heinemann, in 1938, suggested that patients with peptic ulcer disease had an increased metabolic requirement for ascorbic acid [30]. He based this hypothesis on use of the ascorbic acid saturation test in 4 patients with peptic ulcer disease. He found that their requirement was 1.25 mg/kg/day, which was 60% higher than the 0.7 to 0.84 mg/kg/day required by controls [30]. These results were rapidly confirmed by Warren et al. in 5 patients with peptic ulcer disease [31]. In 1953, Breidenbach and Ray fed 10 guinea pigs 1% euganol to induce gastritis; the control group of 11 received only water [32]. After seven days, gastric tissue ascorbic acid content in the gastritis group was 44% lower than the control group and the authors hypothesized that the decrease was secondary to increased utilization of vitamin C at the site of regeneration in the stomach [32]. This is the second example of reduced ascorbic acid in the stomach related to a non-*H. pylori* form of gastritis (i.e., a chemical gastritis).

Destruction of ascorbic acid in the GI Tract

In 1938, Kendall and Chinn suggested that bacterial overgrowth due to achlorhydria caused destruction of ascorbic acid [33]. The following year Alt et al. compared the plasma ascorbic acid levels among 44 patients with achlorhydria associated with iron deficiency anemia or pernicious anemia with controls [34]. They stratified the results by the amount of ascorbic acid in their diets. The plasma ascorbic acid levels in pernicious anemia subjects with adequate dietary intake was 0.57 mg/dL compared 0.73 mg/dL for iron deficiency anemia and 0.87 mg/dL for controls. The pernicious anemia group who had inadequate dietary ascorbic acid had plasma levels of 0.47 mg/dL compared to 0.64 mg/dL for controls. They also evaluated the effect of pH on ascorbic acid stability in vitro and incubation for 3 hours at pH 7.95 resulted in destruction of 65% of the ascorbic acid vs. only 14% at pH 1.45 [34]. More recent studies have suggested a similar method for destruction of ascorbic acid related to hypochlorhydria induced by potent acid suppression [29;35]. These recent studies have also highlighted the potential for PPI associated malabsorption of non-heme iron and vitamin B12 due to reduced release of heme and B12 from ingested food [36–38].

Vitamin C deficiency and ulcer bleeding

Vitamin C is critical for wound repair and several studies have suggested that vitamin C deficiency is associated with an increased risk for peptic ulcer hemorrhage. This hypothesis is consistent with the data shown earlier that bleeding ulcer patients typically had the lower vitamin C levels than ulcer patients who did not bleed. [19;21;22]. Morris suggested that a diet rich in the vitamin C could play a role in the treatment of hemorrhagic peptic ulcer [39]. He presented 2 case histories, the first, a 62-year-old man who presented with “typical scurvy of his leg, with punctate hemorrhages about the hair follicle”. He was given large doses of vitamin C and told to take citrus juice twice daily. The patient returned five years later with similar symptoms and a history of multiple hospitalizations for bleeding from his stomach. He had stopped taking vitamin C and citrus juice; therapy with citrus juice was restarted. At the time of publication, the patient had been adherent to the dietary therapy and had remained symptom free for three years. The second case was a 45 year old man with a five year history of gastric ulcer and two hospitalizations for gastric bleeding. He was started on the same regimen as the first patient and with strict adherence remained symptom free for five years (the time of publication).

In 1955, Weiss et al. evaluated the use of vitamin C in treating bleeding ulcers [40]. The author graded the response of patients to vitamin C, based on recurrence of symptoms and scheduled guaiac tests, as “good” in 12 of 14 subjects with duodenal ulcers and 2 patients with gastric ulcer. More recently, McAlindon et al. evaluated vitamin C for the prevention of aspirin induced gastroduodenal injury and noted a statistically significant reduction in duodenal injury and bleeding in the vitamin C group as assessed by the Lanza score ($p < 0.05$) [41].

H. pylori and vitamin C levels

In the pre-*H. pylori* era, investigators clearly showed that vitamin C deficiency was common in gastritis and peptic ulcer disease and they advocated a diet with fresh fruits and vegetables as a part of the treatment regimen. We now know that *H. pylori* infection underlies both gastritis and gastritis-associated peptic ulcers. Predictably, based on the prior work with gastritis and peptic ulcers, vitamin C levels have consistently been confirmed to be low in patients with *H. pylori* infections. For example, in 1995, Rokkas et al. from Greece reported that gastric juice vitamin C levels were significantly lower in 58 *H. pylori* positive patients than 30 *H. pylori* negative subjects (12.4 mg/dL vs. 29.8 mg/dL, $p < 0.001$) [42]. In 2001

Woodwall et al. determined *H. pylori* status and plasma vitamin C levels of 1,106 U.K. subjects; 716 *H. pylori* positive subjects had vitamin C levels of 64.5% of that of *H. pylori* negative subjects ($p<0.0001$) [43]. Capurso et al. reported similar findings using gastric juice vitamin C levels in 32 *H. pylori* positive patients and 12 healthy controls (0.55 mg/dL vs. 1.49 mg/dL respectively; $p<0.036$) [44]. Finally, Simon et al. using the third National Health and Nutrition Examination Survey in the United States reported the serum ascorbic acid levels of 2,189 subjects with *H. pylori* and 4,557 controls to be 0.71mg/dL and 0.75 mg/dL respectively ($p<0.05$) [45]. In subgroup analysis among whites, age adjusted and multivariate models revealed an inverse association between serum ascorbic acid level and *H. pylori* seropositivity. Each 0.50 mg/dL increase in serum levels was independently associated with a decrease in seropositivity (OR=0.89, $p<0.01$). The presence of CagA-antibody was associated with an even stronger inverse relation in whites (OR=0.31; $p<0.05$) [45].

H. pylori eradication was also shown to improve vitamin C levels. For example, Rokkas et al. treated 58 patients with *H. pylori* infection and a mean pretreatment gastric juice ascorbic acid level of 12.4 mg/dL [42]. Treatment was successful in 45 subjects and the post treatment mean vitamin C level increased to 31.6 mg/dL ($p<0.001$). There was no significant increase when treatment failed (14.2 mg/dL; $P=N.S.$). Banerjee et al. studied gastric tissue ascorbic acid levels among 19 *H. pylori* positive subjects and 10 controls; tissue levels were 2.8 $\mu\text{g/mL}$ vs. 17.8 $\mu\text{g/mL}$ for *H. pylori* positive and negative, respectively ($p<0.0005$) [46]. Following *H. pylori* eradication treatment, 11 of 19 subjects became *H. pylori* negative and their gastric vitamin C level rose from 2.4 $\mu\text{g/mL}$ to 11.2 $\mu\text{g/mL}$ ($p=0.01$) with no significant change in the 8 subjects who failed eradication therapy (3.6 $\mu\text{g/mL}$ to 4.3 $\mu\text{g/mL}$; $P=NS$) [46].

Effect of an acute *H. pylori* infection

Sobala et al. studied the changes in gastric ascorbic acid during an acute *H. pylori* infection in an endoscopist previously known to be *H. pylori* negative [47]. The endoscopist had an gastric ascorbic acid level of 37 $\mu\text{mol/L}$ and a brisk increase in gastric ascorbic acid content (1,862 μg in gastric juice recovered over 45 minutes of nasogastric suction) following a 500 mg intravenous ascorbic acid load 170 days prior to *H. pylori* infection [47]. On day 37 after infection, gastric pH rose to 7.5 and the gastric ascorbic acid level was 2 $\mu\text{mol/L}$ with a minimal response in gastric ascorbic acid content (9 μg) to a 500 mg intravenous load. On day 161, the gastric pH normalized to 2.0 but the gastric ascorbic acid concentration was only 8 $\mu\text{mol/L}$ with a slightly improved response (292 μg) to a 500 mg intravenous load [47].

H. pylori gastritis and vitamin C

H. pylori-induced gastritis inhibits active intra-gastric secretion of ascorbic acid in the stomach and reduces the total vitamin C concentration in the gastric mucosa by converting the majority of the vitamin to dehydroascorbic acid, which is further oxidized to irreversible metabolites such as 2,3-diketo-L-gulonic acid [8;47–49]. Rood et al. studied 145 *H. pylori* infected patients and found elevated gastric pH and damage to the gastric epithelium secondary to *H. pylori* infection to be directly related to decreased gastric ascorbic acid concentration [50]. They showed a direct relationship between increased pH in *H. pylori*-associated gastritis and oxidization of ascorbic acid to the reversible product dehydroascorbic acid and the irreversible product diketogulonic acid. At gastric pH <2 , the average ascorbic acid was found to be 0.29 mg/mL and the average dehydroascorbic acid was 0.32 mg/mL. The average ascorbic acid value dropped to 0.08 mg/mL at pH 2 to 4 and to zero at pH's >6 , while the average dehydroascorbic acid value increased to 0.40 mg/ml at

pH 2 to 4 and fell to 0.23 mg/ml at pH's >6. Dehydroascorbic acid is unstable at higher pH values; consistent with impaired bioavailability of vitamin C being more marked in hypochlorhydric subjects than in normochlorhydric ones. There was also an inverse correlation between damage to the gastric epithelium and ascorbic acid levels. With only superficial damage the mean gastric ascorbic acid level was 0.48 mg/mL, falling to 0.12 mg/mL with moderate damage and 0 mg/mL with severe damage. Rokkas et al. confirmed the significant inverse correlation between the gastritis activity score and gastric juice vitamin C levels [51]. They studied 30 *H. pylori* positive subjects and compared their gastric ascorbic acid levels to 10 controls. They divided the *H. pylori* positive subjects into CagA-positive and CagA-negative groups. The gastric ascorbic acid for the *H. pylori* infected group was 16.3 mg/L compared to 35.5 mg/L for the control group ($p < 0.001$) and 13.8 mg/L for the CagA positive group compared to 24.8 mg/L for the CagA negative group ($p < 0.01$) [51]. They noted no significant difference in gastric pH between the groups to account for the changes in gastric ascorbic acid levels. Since gastric ascorbic acid levels are considerably higher than plasma levels, the authors suggested that impaired active secretion of ascorbic acid plays a role in *H. pylori* induced gastritis [51].

Several groups have also shown that potent acid suppression with PPI therapy is associated with conversion of ascorbic acid to the irreversible product 2,3-diketo-L-gulonic acid leading to a reduction of serum and gastric ascorbic acid levels [29;35;38]. The changes in intragastric concentration of ascorbic acid are most marked in *H. pylori* positive subjects likely related to the more potent acid suppression and the extension of gastritis into corpus mucosa associated with PPI therapy in *H. pylori* infection [52–55]

Intragastric ascorbic acid destruction by bacteria was suggested by Kendall and Chinn in 1938 when they isolated bacteria from gastric aspirates of patients with achlorhydria and showed that they rapidly degraded ascorbic acid [33]. In 1995, Odum and Andersen demonstrated *H. pylori* could itself oxidize and inactivate gastric ascorbic acid. They isolated two factors, one intracellular and one membrane bound, that oxidized ascorbic acid to inactive forms [56].

Vitamin C and acquisition of *H. pylori*

Low ascorbic acid levels itself may also be a risk factor for *H. pylori* acquisition [57]. Goodman et al. surveyed 684 Colombian households with regards to exposures related to infectious disease transmission and dietary intake and determined the *H. pylori* status of children in the household using ^{13}C -urea breath test. After accounting for confounding factors such as socioeconomic variables and transmission related exposures using maximum likelihood logistic regression they noted that daily vitamin C intake of less than 40 mg/day of vitamin C resulted in 12.5 (CI=2.5–62.1) times higher odds of acquiring *H. pylori* compared to those ingesting greater than 120 mg/day. It remains unclear whether vitamin C intake is actually a surrogate for other factors that may correlate with vitamin C intake and also affect transmission such as the level of household hygiene.

Ascorbic acid and gastritis

As noted previously, ascorbic acid deficiency has been associated with all forms of gastritis, whether the etiology was autoimmune (pernicious anemia), chemical (in animals), and bacterial (*H. pylori*) [32;34;42–45]. *H. pylori* infection is the most common cause of gastritis in humans; the organisms attach to the mucosal surface and chronically stimulate production of inflammatory cytokines that results in an influx of polymorphonuclear and mononuclear cells characterized as “acute on chronic” inflammation. Since *H. pylori*-induced gastric inflammation is life-long, it can decimate total body ascorbic acid stores by continually

quenching high levels of ascorbic acid at inflammatory sites and destroying it in a hypochlorhydric environment.

Effect of ascorbic acid on gastric inflammation

The clinical outcome of *H. pylori* infections (duodenal ulcer, gastric ulcer, gastric cancer) varies in different regions. This is best illustrated by the marked differences in the geographic distribution of gastric cancer and with the fact that in many areas the incidence of gastric cancer has decreased rapidly over time [58]. The outcome of an individual *H. pylori* infection can best be correlated with the pattern and severity of gastritis; duodenal ulcer is associated with corpus sparing or antral predominant gastritis and gastric ulcer and gastric cancer with atrophic pangastritis [59]. The pattern of gastritis is determined by an interplay between host factors, bacterial virulence factors, and environmental factors. The fact that in the West, the predominant pattern has changed rapidly from one of atrophic pangastritis with a high prevalence of gastric cancer to one where atrophy is no longer common points to the predominance of environmental factors as the determinant of outcome within a population [59]. The environmental factors that correlate best with the presence of gastric cancer and the change in incidence are diet and the methods of food preservation. Seasonal diets and the use of salt as a primary method of food preservation are associated with atrophic pangastritis and gastric cancer, where as the year around availability of fresh fruits and vegetables protect against it [60]. The increase in the consumption of fresh fruits and vegetables and the use of refrigeration for food preservation have been associated with the significant decrease in gastric cancer incidence in the Western world and with the ongoing decrease in Asia. This has been termed the banana hypothesis [60] and is supported by a large number of published studies and observations [58;61;62]

Since at least 1950, it has been recognized that the precursor lesion or soil within which gastric cancer develops is atrophic gastritis/gastric atrophy [59;63], and, as noted above, fresh fruits and vegetables (i.e., phytonutrients) appear to play a protective role in its pathogenesis. Prior to endoscopy at a dyspepsia clinic, Sobala et al. studied 77 patients who completed a food-frequency questionnaire, with a sensitivity of 73% and specificity of 81% at identifying vitamin C intake less than the recommended daily allowance [64]. The data revealed a significant positive correlation between lower vitamin C intake and severity of gastritis (CC=0.41; p=0.0046). Similarly, Fontham et al. found dietary vitamin C consumption to significantly reduce the risk of gastric cancer precursor lesions while studying 93 subjects with advanced chronic atrophic gastritis and hospital controls (OR =0.40; p<0.01) [65].

Vitamin C is an important phytonutrient and evidence suggests that ascorbic acid may play a protective role against *H. pylori* gastritis and gastric cancer in part by significantly reducing inflammation-associated oxidative damage to the gastric mucosa [66;67]

Correa et al. studied the effect of ascorbic acid and *H. pylori* eradication on the progression of pre-cancerous lesion in Colombian towns with high incidence of gastric cancer [68]. A study of 852 patients with a gastric cancer precursor lesion (non-metaplastic atrophy and intestinal metaplasia) at baseline endoscopy, randomized to treatment groups consisting of placebo, anti-*H. pylori* therapy (amoxicillin 500 mg *tid*, metronidazole 375 mg *tid* and bismuth subsalicylate 262 mg *tid* for 14 days), ascorbic acid supplementation (1 gm b.i.d. until follow up), and anti-*H. pylori* therapy with ascorbic acid supplementation. Follow-up endoscopy at 72 months revealed a significantly higher relative risk of histologic regression in the anti-*H. pylori* therapy, the ascorbic acid group and the anti-*H. pylori* therapy plus ascorbic acid group in relation to placebo. In the metaplastic atrophy group the relative risk of regression in comparison to placebo was 4.8 (95% CI: 1.6–14.2) for anti-*H. pylori* group,

5.0 (95% CI: 1.7–14.4) for ascorbic acid group and 6.3 (95% CI: 1.6–24.3) for anti-*H. pylori* plus ascorbic acid group. In the intestinal metaplasia group the relative risk of regression compared to placebo was 3.1 (95% CI: 1–9.3) for anti-*H. pylori* group, 3.3 (95% CI: 1.1–9.5) for ascorbic acid group and 4.1 (95% CI: 1.1–15.9) for anti-*H. pylori* plus ascorbic acid group [68].

Intragastric formation of carcinogenic N-nitroso compounds (NOC) has been proposed to be possibly involved in gastric carcinogenesis [54]. NOCs are generated in a nitrosation reaction between gastric nitrite and gastric nitrogenous organic compounds derived from diet [69;70]. NOC generation is inhibited by ascorbic acid, which scavenges nitrites in gastric juice by converting it to nitric oxide [70;71]. The ability of ascorbic acid to scavenge nitrite is dependent on the ratio of vitamin C to nitrite and gastric pH. Increased NOC generation occurs with a decreased ratio of vitamin C to nitrite and pH >2–4 and [72] elevated gastric pH results in conversion of active ascorbic acid to inactive dehydroascorbic acid as well as higher levels of nitrite generation [52]. Several recent studies have linked the use of PPI to decreased vitamin C to nitrite ratio, an effect especially marked in *H. pylori* infected patients [35]. For example Mowat et al. demonstrated statistically significant elevation in pH, an increase in fasting and post nitrate bolus nitrite levels, and a decrease in active and total vitamin C in individuals receiving 40 mg of omeprazole daily [35]. The changes in pH, nitrite levels and vitamin C levels were significantly higher in *H. pylori* positive subjects compared to uninfected individuals [29;73]. These studies suggest that PPI therapy in *H. pylori* infected individuals results in not only a more marked rise in intragastric pH and gastric inflammation but also higher nitrite and lower ascorbic acid levels [53;74].

Ascorbic acid and oxidative damage to the gastric mucosa

Ascorbic acid is thought to decrease oxidative damage to the gastric mucosa by scavenging free radicals and NOCs and attenuating the *H. pylori* induced inflammatory cascade. In vitro studies using activated polymorphonuclear leukocytes have shown that oxidation of extracellular ascorbate by activated PMN's is stoichiometric with oxygen consumption [75]. The stoichiometric consumption of extracellular ascorbate with respect to oxygen is consistent with the notion that NADPH oxidase production of superoxide on the outside of the cell membrane can be scavenged by ascorbic acid. Electron paramagnetic resonance spectroscopy has also demonstrated that ascorbyl radicals produced by scavenging of oxygen radicals by ascorbic acid in the gastric mucosa is 2-fold greater in *H. pylori*-infected gastric mucosa compared to controls [76]. Finally, the concentration of the ascorbyl radical also correlates with markers of radical generation and tissue damage [76]. Of interest, genetic polymorphism in SVCT2 have been shown to be associated with protection against gastric cancer [77]. However, it remains to be shown whether the protective polymorphism is associated with a consistent change in gastric mucosal ascorbic acid levels.

Ascorbic acid supplementation has also been shown to attenuate the *H. pylori*-induced inflammatory response. In one study 30 *H. pylori* infected patients with reflux esophagitis were randomized into a groups that received 20 mg of omeprazole with or without 1,200 mg of ascorbic acid daily for 2 weeks and those receiving ascorbic acid had significantly lower levels of gastric corpus mucosal IL-8 and neutrophilic infiltration compared to those who did not ($p < 0.05$) [78].

Ascorbic acid and effectiveness of *H. pylori* eradication therapy

In vitro studies show that ascorbic acid produced up to 90% inhibition of multiple *H. pylori* strains with the highest inhibition occurring at low pH, possibly due to increased stability of

vitamin C at low pH [79]. In vivo studies involving 7 days of vitamin C therapy (10 mg/day) given to *H. pylori* infected gerbils also resulted in a decrease from 10^5 colony forming units in control to 10^3 in the treatment group [79]. Jarosz et al. randomized patients with *H. pylori* infection and dyspepsia into control (n=24) and treatment (n=27) groups [80]. The treatment group received 5 grams of vitamin C daily for four weeks and 8 patients achieved *H. pylori* eradication, measured by urease test of gastric biopsy, in the treatment group compared to no patients in the control group (P=0.006) (Table 4). Zojaji et al. randomized 312 patients to two groups; one group received amoxicillin, metronidazole, bismuth and omeprazole for two weeks and the other the same regimen plus 500 mg of ascorbic acid daily [81]. The addition of ascorbic acid resulted in an increase in eradication from 48.8% to 78% at 4 weeks ($p<0.0001$) (Table 4). Sezikli et al. randomized 160 patients to receive either lansoprazole, amoxicillin, clarithromycin, and bismuth subcitrate or this regimen plus 500 mg ascorbic acid b.i.d. and vitamin E (200 IU, b.i.d.) for 2 weeks [82]. *H. pylori* eradication increased from 60% to 93.5% with the addition of the vitamins ($p<0.005$) (Table 4). Chuang et al. randomized 171 patients into three therapies for 1 week. Group 1 received 20 mg omeprazole daily, 1 gram amoxicillin daily and 250 mg of clarithromycin twice daily, group 2 received the same regimen as group 1 plus 500 mg of vitamin C twice daily and group 3 received omeprazole, amoxicillin and 500 mg of clarithromycin twice daily without vitamin C supplementation [83]. The eradication rate increased from 68% in group 1 to 85% with the addition of ascorbic acid in group 2 ($p=0.03$). The difference in eradication rate was not significant between group 2 and group 3 suggesting that vitamin C supplementation might allow a reduction in the dose of clarithromycin required to eradicate *H. pylori* (Table 4). Kaboli et al. found similar results in 214 patients randomized to 250 mg clarithromycin plus ascorbic acid twice daily versus 500 mg clarithromycin twice daily (86.8% versus 89% respectively; $p=0.623$) (Table 4) [84]. Kamiji and Oliveira from Portugal studied 38 *H. pylori* infected patients without previous antibiotic therapy and 8 patients with 2 previous treatment failures [85]. The 38 patients without previous therapy were divided into a control group (n=17) and a group receiving 5 grams of vitamin C daily for 28 days. No patients in the treatment or control group achieved eradication. The 8 patients with previous antibiotic treatment failure also failed high dose vitamin C therapy for 28 days (Table 4). Chuang et al. studied 104 *H. pylori* infected patients randomized to receive either 30 mg lansoprazole, 1 gm amoxicillin, and 500 mg metronidazole twice daily for 1 week or lansoprazole, amoxicillin, metronidazole plus 250 mg vitamin C and 200 mg vitamin E twice daily for 1 week, followed by 250 mg vitamin C and 200 mg vitamin E once daily for 6 consecutive weeks [86]. In the patients infected with metronidazole susceptible isolates, the triple therapy only group had a higher eradication rate than triple therapy plus vitamin group (80% versus 53.1%; $p=0.02$), with the authors suggesting a difference in patient compliance and bacterial density as the cause for the result. No statistical difference in eradication was noted in the metronidazole resistant group (26.3% versus 21.7%; $p=NS$) [86].

Conclusion

Gastritis, whether associated with autoimmune process, chemical injury or infection with *H. pylori* underlies the development of peptic ulcer disease and gastric cancer. Ascorbic acid plays a key role in healing and protection of the gastric mucosa from injurious insults. Vitamin C deficiency has repeatedly been linked with peptic ulcer disease and its complications. Its role in scavenging free radicals and reducing the inflammatory cascade, particularly in *H. pylori* induced gastritis, play a major preventive role in reducing the consequences of gastric inflammation including in reducing the deleterious effects of reactive oxygen species and NOC. These effects are reflected in population-based epidemiologic studies showing negative correlations between vitamin C intake and gastric cancer and endoscopic studies suggesting regression of precancerous lesion with ascorbic acid supplementation. Ascorbic acid supplementation has been associated with a decreased

incidence of bleeding from peptic ulcer disease and with a reduction in NSAID-associated gastric mucosal damage. Pharmacologic doses of ascorbic acid also may improve the effectiveness of *H. pylori* eradication therapy. Occasionally, looking back can help plot the way forward.

Acknowledgments

Dr. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases Center, DK067366 and CA116845. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the VA or NIH. Dr. Graham is a unpaid consultant for Novartis in relation to vaccine development for treatment or prevention of *H. pylori* infection. Dr. Graham is also a paid consultant for Otsuka Pharmaceuticals regarding diagnostic testing until has received royalties on the Baylor College of Medicine patent covering materials related to ¹³C-urea breath test. Dr. Aditi has nothing to declare. The authors thank Dr. Rassa Shahidzadeh for helping to get this projects started.

References

1. Carpenter, KJ. The history of scurvy & vitamin C. New York: Cambridge University Press; 1986.
2. Pellegra. Stroudsburch: Hutchinson Ross Publishing Company; 1981.
3. Carpenter, KJ. A disease, a cause, and a cure. Berkeley: University of California Press; 2000. Beriberi, white rice, and vitamin B.
4. Wilson JX. Regulation of vitamin C transport. Annu Rev Nutr. 2005; 25:105–125. [PubMed: 16011461]
5. Tsukaguchi H, Tokui T, Mackenzie B, et al. A family of mammalian Na⁺-dependent L-ascorbic acid transporters. Nature. 1999; 399:70–75. [PubMed: 10331392]
6. Waring AJ, Schorah CJ. Transport of ascorbic acid in gastric epithelial cells in vitro. Clin Chim Acta. 1998; 275:137–149. [PubMed: 9721072]
7. Boyer JC, Campbell CE, Sigurdson WJ, et al. Polarized localization of vitamin C transporters, SVCT1 and SVCT2, in epithelial cells. Biochem Biophys Res Commun. 2005; 334:150–156. [PubMed: 15993839]
8. Wilson JX. The physiological role of dehydroascorbic acid. FEBS Lett. 2002; 527:5–9. [PubMed: 12220624]
9. Wrieden WL, Hannah MK, Bolton-Smith C, et al. Plasma vitamin C and food choice in the third Glasgow MONICA population survey. J Epidemiol Community Health. 2000; 54:355–360. [PubMed: 10814656]
10. Ingalls TH, Warren HA. Asymptomatic scurvy: its relation to wound healing and its incidence in patients with peptic ulcer. N Engl J Med. 1937; 217:443–446.
11. Szent-Gyorgyi A. Observations on the function of peroxidase systems and the chemistry of the adrenal cortex: Description of a new carbohydrate derivative. Biochem J. 1928; 22:1387–1409. [PubMed: 16744155]
12. Szent-Gyorgyi A. Identification of vitamin C. Nature. 1933; 131:225–226.
13. Waugh WA, King CG. Isolation and identification of vitamin C. J Biol Chem. 1932; 97:325–331.
14. Tillmans J. Das antiskorbutische vitamin. Z Untersuch Lebensm. 1930; 60:34.
15. Van Eekelen M, Heinemann M. Critical remarks on the determination of urinary excretion of ascorbic acid. J Clin Invest. 1938; 17:293–299. [PubMed: 16694573]
16. Harris LJ, Abbassy MA, Yudkin J. Vitamin in human nutrition. Vitamin C reserves of subjects of the voluntary hospital class. Lancet. 1936; 1:1488–1490.
17. Archer HE, Graham G. The subscurvy state in relation to gastric and duodenal ulcer. Lancet. 1936; ii:383–385.
18. Ingalls TH. Studies on the urinary excretion and blood concentration of ascorbic acid in infantile scurvy. J Pediatr. 1937; 10:577–591.
19. Field H Jr, Robinson WD, Melnick D. Vitamins in peptic ulcer. Ann Intern Med. 1940; 14:378–392.

20. Riggs H, Reinhold J, Boyles R. Qualitative circulatory deficiencies observed in peptic ulcer. *Am J Dig Dis*. 1941; 8:383–385.
21. Portnoy B, Wilkinson JF. Vitamin C deficiency in peptic ulceration. *Br Med J*. 1938; 1:554–560. [PubMed: 20781309]
22. Crescenzo VM, Cayer D. Plasma vitamin C levels in patients with peptic ulcer. Response to oral load test of ascorbic acid. *Gastroenterology*. 1947; 8:754–761. [PubMed: 20251629]
23. Freeman JT, Hafkesbring R. Comparative studies of ascorbic acid levels in gastric secretion and blood. III. Gastrointestinal diseases. *Gastroenterology*. 1957; 32:878–886. [PubMed: 13438146]
24. Ludden JB, Flexner J, Wright IS. Studies on ascorbic acid deficiency in gastric diseases: Incidence, diagnosis, and treatment. *Am J Dig Dis*. 1941; 8:249–252.
25. Sippy B. Gastric and duodenal ulcer; medical cure by an efficient removal of gastric juice corrosion. *J A M A*. 1915; 64:1625–1630.
26. Ebbesen I, Rasmussen M. Some investigations on the ascorbic acid content in serum from patients suffering from peptic ulcer. *Acta Med Scand*. 1944; 117:507.
27. Davidson PB. The development of deficiency disease during therapeutic diets. *JAMA*. 1928; 90:1014–1015.
28. Platt R. Scurvy as the result of dietetic treatment. *Lancet*. 1936; ii:366–367.
29. Henry EB, Carswell A, Wirz A, et al. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. *Aliment Pharmacol Ther*. 2005; 22:539–545. [PubMed: 16167970]
30. Heinemann M. Requirements for vitamin C in man. *J Clin Invest*. 1938; 17:671–676. [PubMed: 16694613]
31. Warren HA, Pijoan M, Emery ES Jr. Ascorbic acid requirements in patients with peptic ulcer. *NEJM*. 1939; 220:1061–1063.
32. Breidenback AW, Ray FE. Gastric ascorbic acid in the gastritic guinea pig. *Science*. 1953; 118:557.
33. Kendall AI, Chinn H. Decomposition of ascorbic acid by certain bacteria. *J Infect Dis*. 1938; 62:330–336.
34. Alt HA, Chinn H, Farmer CJ. The blood plasma ascorbic acid in patients with achlorhydria. *Am J Med Sci*. 1939; 197:222–232.
35. Mowat C, McColl KE. Alterations in intragastric nitrite and vitamin C levels during acid inhibitory therapy. *Best Pract Res Clin Gastroenterol*. 2001; 15:523–537. [PubMed: 11403544]
36. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). *Ann Intern Med*. 1994; 120:211–215. [PubMed: 8273984]
37. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. *J Clin Gastroenterol*. 1992; 14:288–292. [PubMed: 1607604]
38. Golubov J, Flanagan P, Adams P. Inhibition of iron absorption by omeprazole in rat model. *Dig Dis Sci*. 1991; (36):405–408. [PubMed: 2007356]
39. Morris GE. Avitaminosis C in 1953: A clinical study. *Ann Intern Med*. 1958; 5:393–394.
40. Weiss S, Weiss J, Weiss B. Gastrointestinal haemorrhage: therapeutic evaluation of bioflavonoids. Report on 55 cases. *Am J Gastroenterol*. 1955; 24:523–532. [PubMed: 13268398]
41. McAlindon ME, Muller AF, Filipowicz B, et al. Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers. *Gut*. 1996; 38:518–524. [PubMed: 8707080]
42. Rokkas T, Papatheodorou G, Karameris A, et al. Giannikos N. *Helicobacter pylori* infection and gastric juice vitamin C levels. Impact of eradication. *Dig Dis Sci*. 1995; 40:615–621. [PubMed: 7895555]
43. Woodward M, Tunstall-Pedoe H, McColl K. *Helicobacter pylori* infection reduces systemic availability of dietary vitamin C. *Eur J Gastroenterol Hepatol*. 2001; 13:233–237. [PubMed: 11293441]
44. Capurso G, Ricci R, Panzuto F, Baccini F, et al. Intragastric ascorbic but not uric acid is depleted in relation with the increased pH in patients with atrophic body gastritis and *H. Pylori* gastritis. *Helicobacter*. 2003; 8:300–306. [PubMed: 12950602]

45. Simon JA, Hudes ES, Perez-Perez GI. Relation of serum ascorbic acid to *Helicobacter pylori* serology in US adults: the Third National Health and Nutrition Examination Survey. *J Am Coll Nutr.* 2003; 22:283–289. [PubMed: 12897042]
46. Banerjee S, Hawksby C, Miller S, et al. Effect of *Helicobacter pylori* and its eradication on gastric juice ascorbic acid. *Gut.* 1994; 35:317–322. [PubMed: 8150339]
47. Sobala GM, Crabtree JE, Dixon MF, et al. Acute *Helicobacter pylori* infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. *Gut.* 1991; 32:1415–1418. [PubMed: 1752479]
48. O'Connor HJ, Schorah CJ, Habibzadah N, et al. Vitamin C in the human stomach: relation to gastric pH, gastroduodenal disease, and possible sources. *Gut.* 1989; 30:436–442. [PubMed: 2714677]
49. Waring AJ, Drake IM, Schorah CJ, et al. Ascorbic acid and total vitamin C concentrations in plasma, gastric juice, and gastrointestinal mucosa: effects of gastritis and oral supplementation. *Gut.* 1996; 38:171–176. [PubMed: 8801192]
50. Rood JC, Ruiz B, Fontham ET, et al. *Helicobacter pylori*-associated gastritis and the ascorbic acid concentration in gastric juice. *Nutr Cancer.* 1994; 22:65–72. [PubMed: 11304911]
51. Rokkas T, Liatsos C, Petridou E, et al. Relationship of *Helicobacter pylori* CagA(+) status to gastric juice vitamin C levels. *Eur J Clin Invest.* 1999; 29:56–62. [PubMed: 10092990]
52. Mowat C, Carswell A, Wirz A, et al. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. *Gastroenterology.* 1999; 116:813–822. [PubMed: 10092303]
53. Kuipers EJ, Uytendin AM, Pena AS, et al. Increase of *Helicobacter pylori*-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. *Am J Gastroenterol.* 1995; 90:1401–1406. [PubMed: 7661157]
54. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res.* 1992; 52:6735–6740. [PubMed: 1458460]
55. Graham DY, Opekun AR, Yamaoka Y, et al. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. *Aliment Pharmacol Ther.* 2003; 17:193–200. [PubMed: 12534403]
56. Odum L, Andersen LP. Investigation of *Helicobacter pylori* ascorbic acid oxidating activity. *FEMS Immunol Med Microbiol.* 1995; 10:289–294. [PubMed: 7773246]
57. Goodman KJ, Correa P, Tengana Aux HJ, et al. Nutritional factors and *Helicobacter pylori* infection in Colombian children. *J Pediatr Gastroenterol Nutr.* 1997; 25:507–515. [PubMed: 9360204]
58. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. *Epidemiol Rev.* 1986; 8:1–27. [PubMed: 3533579]
59. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. *J Gastroenterol.* 2010; 45:1–8. [PubMed: 19714291]
60. Graham DY. *Helicobacter pylori* infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. *Gastroenterology.* 1997; 113:1983–1991. [PubMed: 9394739]
61. Sugimura T, Sugano H, Terada M, et al. First International Workshop of the Princess Takamatsu Cancer Research Fund: intestinal metaplasia and gastric cancer. *Mol Carcinog.* 1994; 11:1–7. [PubMed: 7916984]
62. Correa P, Cuello C, Fajardo LF, et al. Diet and gastric cancer: nutrition survey in a high-risk area. *J Natl Cancer Inst.* 1983; 70:673–678. [PubMed: 6572755]
63. Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. *Ann Intern Med.* 1951; 36:1331–1348. [PubMed: 14838496]
64. Sobala GM, Schorah CJ, Sanderson M, et al. Ascorbic acid in the human stomach. *Gastroenterology.* 1989; 97:357–363. [PubMed: 2744355]
65. Fontham E, Zavala D, Correa P, et al. Diet and chronic atrophic gastritis: a case-control study. *J Natl Cancer Inst.* 1986; 76:621–627. [PubMed: 3457199]

66. Iacopini F, Consolazio A, Bosco D, et al. Oxidative damage of the gastric mucosa in *Helicobacter pylori* positive chronic atrophic and nonatrophic gastritis, before and after eradication. *Helicobacter*. 2003; 8:503–512. [PubMed: 14535997]
67. Drake IM, Davies MJ, Mapstone NP, et al. Ascorbic acid may protect against human gastric cancer by scavenging mucosal oxygen radicals. *Carcinogenesis*. 1996; 17:559–562. [PubMed: 8631145]
68. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-*Helicobacter pylori* therapy. *J Natl Cancer Inst*. 2000; 92:1881–1888. [PubMed: 11106679]
69. Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. *Cancer Lett*. 1995; 93:17–48. [PubMed: 7600541]
70. Mirvish SS. Inhibition by vitamins C and E of in vivo nitrosation and vitamin C occurrence in the stomach. *Eur J Cancer Prev*. 1996; 5 (Suppl 1):131–136. [PubMed: 8972308]
71. Mirvish SS, Wallcave L, Eagen M, et al. Ascorbate-nitrite reaction: possible means of blocking the formation of carcinogenic N-nitroso compounds. *Science*. 1972; 177:65–68. [PubMed: 5041776]
72. Iijima K, Fyfe V, McColl KE. Studies of nitric oxide generation from salivary nitrite in human gastric juice. *Scand J Gastroenterol*. 2003; 38(3):246–252. [PubMed: 12737438]
73. Mowat C, Williams C, Gillen D, et al. Omeprazole, *Helicobacter pylori* status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. *Gastroenterology*. 2000; 119:339–347. [PubMed: 10930369]
74. Verdu EF, Armstrong D, Fraser R, et al. Effect of *Helicobacter pylori* status on intragastric pH during treatment with omeprazole. *Gut*. 1995; 36:539–543. [PubMed: 7737560]
75. Hemila H, Roberts P, Wikstrom M. Activated polymorphonuclear leucocytes consume vitamin C. *FEBS Lett*. 1984; 178:25–30. [PubMed: 6094256]
76. Drake IM, Mapstone NP, Schorah CJ, et al. Reactive oxygen species activity and lipid peroxidation in *Helicobacter pylori* associated gastritis: relation to gastric mucosal ascorbic acid concentrations and effect of H pylori eradication. *Gut*. 1998; 42:768–771. [PubMed: 9691912]
77. Wright ME, Andreotti G, Lissowska J, et al. Genetic variation in sodium-dependent ascorbic acid transporters and risk of gastric cancer in Poland. *Eur J Cancer*. 2009; 45:1824–1830. [PubMed: 19243932]
78. Yoshinaga M, Ohtani A, Harada N, et al. Vitamin C inhibits corpus gastritis in *Helicobacter pylori*-infected patients during acid-suppressive therapy. *J Gastroenterol Hepatol*. 2001; 16:1206–1210. [PubMed: 11903736]
79. Zhang HM, Wakisaka N, Maeda O, et al. Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: *Helicobacter pylori*. *Cancer*. 1997; 80:1897–1903. [PubMed: 9366290]
80. Jarosz M, Dzieniszewski J, Broszka-Ufniaz E, et al. Effects of high dose vitamin C treatment on *Helicobacter pylori* infection and total vitamin C concentration in gastric juice. *Eur J Cancer Prev*. 1998; 7:449–454. [PubMed: 9926292]
81. Zojaji H, Talaie R, Mirsattari D, et al. The efficacy of *Helicobacter pylori* eradication regimen with and without vitamin C supplementation. *Dig Liver Dis*. 2009; 41:644–647. [PubMed: 19493713]
82. Sezikli M, Cetinkaya ZA, Sezikli H, et al. Oxidative stress in *Helicobacter pylori* infection: does supplementation with vitamins C and E increase the eradication rate? *Helicobacter*. 2009; 14:280–285. [PubMed: 19674132]
83. Chuang CH, Sheu BS, Kao AW, et al. Adjuvant effect of vitamin C on omeprazole-amoxicillin-clarithromycin triple therapy for *Helicobacter pylori* eradication. *Hepatogastroenterology*. 2007; 54(73):320–324. [PubMed: 17419283]
84. Kaboli SA, Zojaji H, Mirsattari D, et al. Effect of addition of vitamin C to clarithromycin-amoxicillin-omeprazole triple regimen on *Helicobacter pylori* eradication. *Acta Gastroenterol Belg*. 2009; 72:222–224. [PubMed: 19637777]
85. Kamiji MM, Oliveira RB. Effect of vitamin C administration on gastric colonization by *Helicobacter pylori*. *Arq Gastroenterol*. 2005; 42:167–172. [PubMed: 16200253]

86. Chuang CH, Sheu BS, Huang AH, et al. Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible *Helicobacter pylori* infection. *Helicobacter*. 2002; 7:310–316. [PubMed: 12390211]

Figure 1.
Urinary ascorbic acid excretion in 6 subjects with gastric ulcers compared to minimal normal excretion of 13 mg/day
Adapted from [17]

Figure 2.
Plasma and Gastric ascorbic acid levels in controls versus subjects with gastric pathology
Adapted from (23]

Table 1

Plasma ascorbic acid levels as established in 1937

State of Nutrition	Category	Plasma Ascorbic Acid
Optimum	Saturation	1.00 – 2.00 mg/dL
	Normal	0.70 – 1.00 mg/dL
	Low normal	0.50 – 0.70 mg/dL
Suboptimum		0.30 – 0.50 mg/dL
Deficiency	Asymptomatic Scurvy	0.15 – 0.30 mg/dL
	Scurvy	0.00 – 0.15 mg/dL

Adapted from [10]

Table 2

Plasma ascorbic acid concentration, urinary excretion and dose required for saturation amongst peptic ulcer disease and control subjects

Group (n)	Plasma AA (mg/dL)	Urinary Excretion(mg/day)	Dose needed to reach saturation (mg)
Control [26]	0.6–1.85	29	500–1000
Hospital control [25]	0.6–1.85	17	1252
PUD w/o bleed [25]	0.42	7	3691
PUD w/ bleed [31]	0.34	7	4543

Adapted from [21]

Table 3

Plasma ascorbic acid levels (fasting and hourly after a 1,000 mg ascorbic acid oral challenge) in ulcer patients and hospital controls

Group (n)	Fasting (mg/dL)	Hours post infusion (mg/dL)	Hours post infusion (mg/dL)	Hours post infusion (mg/dL)
		1	2	3
Bleeding Ulcer [7]	0.07	0.25	0.44	0.63
Active Ulcer [13]	0.22	0.53	0.90	1.0
Hx of Ulcer [10]	0.34	0.70	1.4	1.7
Control [25]	0.64	1.0	1.63	1.83

Adapted from [22]

Table 4

Effect of ascorbic acid supplementation on *H. pylori* eradication

Study	Regimen	AA dose mg/day	Duration (weeks)	Sample (n)	Eradication (%)	p value
Jarosch et al. [80]	Placebo	0	4	24	0	
	Ascorbate	5,000	4	27	29.6	p=0.006
Zojjaji et al. [81]	O.A.M.B	0	2	162	48.8	
	O.A.M.B + ascorbate	500	2	150	78	p<0.0001
Sezikli et al. [82]	L.A.C.B	0	2	80	60	
	L.A.C.B + ascorbate	500	2	80	93.5	p<0.005
Chuang et al. [83]	O.A.C250	0	1	55	68	
	O.A.C250	500	1	61	85	p=0.03
	O.A.C500	0	1	55		
Kaboli et al. [84]	O.A.C250	500	2	114	86.8	p=0.623
	O.A.C500	0	2	100	89	
Kamiji et al. [85] (Protocol I)	Placebo	0	4	17	0	0-15% (95% conf inter)
	Ascorbate	5000	4	21	0	
(Protocol II) [85]	Ascorbate	5000	4	8	0	
Chuang et al-metronidazole resistant [86]	L.A.M	0	1	19	26.3	P=NS
	L.A.M + vitamin C,E	500	7	23	21.7	
Chuang et al-metronidazole susceptible [86]	L.A.M	0	1	30	80	p=0.02
	L.A.M + vitamin C,E	500	7	32	53.1	

O = omeprazole, A = amoxicillin, C = clarithromycin, B = Bismuth, L = lansoprazole, M = metronidazole